TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34255745

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg in week 1, 1000 mg in week 2, 2000 mg daily for weeks 3-12)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 23
Study: 32511207

Group type: EXPERIMENTAL
Intervention: Saline-air hysterosalpingo-contrast sonography (SA-HyCoSy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Modified hysterosalpingogram (mHSG)
Number of subjects: 19
Study: 35649699

Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (sNfL) levels during periods of active inflammation (Gd+ lesions present or recently present)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mean sNfL levels during periods of remission (no Gd+ lesions present or recently present)
Number of subjects: 85
Study: 33541306

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual infusion (MI) of propofol anesthesia
Number of subjects: 40
Study: 32317100

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stents (RES)
Number of subjects: 1914

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1914
Study: 33454272

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily for 6 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 97
Study: 32000731

Group type: EXPERIMENTAL
Intervention: Nodule spiculation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Larger nodule size
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Presentation with haemoptysis
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Presentation with weight loss
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Recommendation for urgent review by the reporting radiologist
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Female GP gender
Number of subjects: 152

Group type: COMPARATOR
Intervention: Haemoptysis with a normal chest CT scan
Number of subjects: 152

Group type: COMPARATOR
Intervention: Isolated mediastinal lymphadenopathy
Number of subjects: 152
Study: 35635652

Group type: EXPERIMENTAL
Intervention: Regorafenib dose-escalation therapy starting at 80 mg/day, escalating to 120 mg/day in Week 2 and 160 mg/day in Week 3 if no severe toxicities observed.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Regorafenib standard therapy (implied as a comparison).
Number of subjects: 57
Study: 35381742

Group type: EXPERIMENTAL
Intervention: MUC1-GEM-PBCA-NP
Number of subjects: 0
Study: 32671481

Group type: EXPERIMENTAL
Intervention: Denosumab co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Placebo co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)
Number of subjects: 956
Study: 35507499

Group type: EXPERIMENTAL
Intervention: Ablation plus ICD
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional medical therapy plus ICD
Number of subjects: 121
Study: 34658253

Group type: EXPERIMENTAL
Intervention: Insulin infusion to mimic prandial insulin response (full dose, 80% dose, 60% dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 0.65 ng/kg/min (nonsuppressed day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 0.65 ng/kg/min (suppressed day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis adjusted for age, sex, weight, and insulin dose
Number of subjects: 54
Study: 33836922

Group type: EXPERIMENTAL
Intervention: Two-stage diagnostic classification system using an extremely randomized trees machine learning algorithm.
Number of subjects: 73
Study: 32973120

Group type: EXPERIMENTAL
Intervention: Lowest SES tertile
Number of subjects: 525

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 525
Study: 34954718

Group type: EXPERIMENTAL
Intervention: Monthly HIV self-testing and quarterly in-clinic testing
Number of subjects: 110

Group type: COMPARATOR
Intervention: Quarterly in-clinic HIV testing alone (standard of care)
Number of subjects: 110
Study: 32533548

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) for eight sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional medications and psycho-education (control group)
Number of subjects: 50
Study: 35383832

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily
Number of subjects: 12964
Study: 32615579

Group type: EXPERIMENTAL
Intervention: Cow’s milk-based infant formula with added prebiotic blend (PDX/GOS)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cow’s milk-based infant formula (Control)
Number of subjects: 161
Study: 32704380

Group type: EXPERIMENTAL
Intervention: Contraception Choices website (n = 464)
Number of subjects: 927

Group type: COMPARATOR
Intervention: Waiting-list control group (n = 463)
Number of subjects: 927
Study: 36244667

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX, 0.6 μg/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no DEX)
Number of subjects: 96
Study: 33557798

Group type: EXPERIMENTAL
Intervention: Female veterans
Number of subjects: 85
Study: 33612197

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Behavioral self-control therapy (BSCT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Brief advice (BA)
Number of subjects: 160
Study: 32150255

Group type: EXPERIMENTAL
Intervention: NKTR-181 (oxycodegol)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 34724084

Group type: EXPERIMENTAL
Intervention: Individual nutritional counseling every 2 weeks during therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: No nutritional counseling (control group)
Number of subjects: 46
Study: 34312935

Group type: COMPARATOR
Intervention: MDDS (short disease duration)
Number of subjects: 45

Group type: COMPARATOR
Intervention: MDDL (long disease duration)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Correlation analyses
Number of subjects: 45
Study: 32218561

Group type: EXPERIMENTAL
Intervention: Consultation with General Practitioners (GPs) for NSLBP
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: LBP episode of less than 12 weeks
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Maladaptive psychosocial factors
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 115
Study: 35152574

Group type: EXPERIMENTAL
Intervention: Tiaoshen Qianyang acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture (Control)
Number of subjects: 120
Study: 34774334

Group type: EXPERIMENTAL
Intervention: Etelcalcetide (5 mg per dose intravenously)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 36397435

Group type: EXPERIMENTAL
Intervention: C-MAC D-blade videolaryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 90
Study: 32483253

Group type: EXPERIMENTAL
Intervention: Visual Word Form Area (VWFA) activity during encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induced high gamma power (iHGP) in posterior superior temporal gyrus (STGp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task performance
Number of subjects: 0
Study: 33435287

Group type: EXPERIMENTAL
Intervention: Controlled-feeding Continuous Energy Restriction (CER) - 25% daily energy restriction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Controlled-feeding Intermittent Energy Restriction (IER) - alternating ad libitum and 75% energy restriction days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both IER and CER
Number of subjects: 30
Study: 35266148

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (POIT) with AR101
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blinded placebo-controlled peanut challenge (DBPCFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline peanut-reactive TH2A cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: POIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR101 therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peanut-reactive Treg cell frequency
Number of subjects: 0
Study: 33595923

Group type: EXPERIMENTAL
Intervention: Aortic pulsatility index (API)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Cardiac power output (CPO)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Fick cardiac index (CI)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Pulmonary artery pulsatility index (PAPI)
Number of subjects: 433
Study: 32539121

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (initial dose of 10 mg/kg followed by 5 mg/kg after 24 hours and a second 5 mg/kg dose after 48 hours)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 146
Study: 35012375

Group type: EXPERIMENTAL
Intervention: Hospital with visible greenspaces
Number of subjects: 74

Group type: COMPARATOR
Intervention: Hospital without visible greenspaces
Number of subjects: 74
Study: 34156002

Group type: EXPERIMENTAL
Intervention: Endonasal blockade of the nasopalatine nerve at the point of its emergence from the pterygopalatine ganglion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Anesthesia of the nasopalatine nerve at its entry into the incisive canal
Number of subjects: 52
Study: 34273071

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All other azole antifungals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole (CYP 3A inhibition confirmed with midazolam)
Number of subjects: 0
Study: 32282386

Group type: COMPARATOR
Intervention: DPE + CEI
Number of subjects: 116

Group type: COMPARATOR
Intervention: DPE + PIEB
Number of subjects: 116

Group type: COMPARATOR
Intervention: EP + CEI
Number of subjects: 116
Study: 36335411

Group type: COMPARATOR
Intervention: Oral or sublingual mixed respiratory bacterial lysates (BLs)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Injected mixed respiratory bacterial vaccines (BVs)
Number of subjects: 1658
Study: 32680615

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 20
Study: 35534349

Group type: EXPERIMENTAL
Intervention: Synergy drug eluting stent (DES)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Xience drug eluting stent (DES)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both Synergy and Xience stents
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Synergy stents
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Xience stents
Number of subjects: 170
Study: 32209907

Group type: EXPERIMENTAL
Intervention: Cruciate incision
Number of subjects: 209

Group type: COMPARATOR
Intervention: Circular incision
Number of subjects: 209

Group type: COMPARATOR
Intervention: Prophylactic mesh
Number of subjects: 209
Study: 35435203

Group type: EXPERIMENTAL
Intervention: RPE/C group (alternate rapid palatal expansions and constrictions with facemask protraction)
Number of subjects: 34

Group type: COMPARATOR
Intervention: RPE group (rapid palatal expansion with facemask protraction)
Number of subjects: 34
Study: 33730122

Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor (NGF) injection into SCM
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline solution injection into SCM
Number of subjects: 28
Study: 35232309

Group type: EXPERIMENTAL
Intervention: Restrictions on potential allocations to ensure balance across study arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fisher–Bailey validity
Number of subjects: 0
Study: 35043507

Group type: EXPERIMENTAL
Intervention: Topically administered purified clinoptilolite-tuff (PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 0
Study: 32757963

Group type: EXPERIMENTAL
Intervention: PCT-guided discontinuation of antimicrobials
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 266
Study: 33960817

Group type: EXPERIMENTAL
Intervention: ceftobiprole
Number of subjects: 633

Group type: COMPARATOR
Intervention: comparator antibiotics
Number of subjects: 633
Study: 32885600

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastric bypass
Number of subjects: 0
Study: 34171870

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 0
Study: 32823510

Group type: EXPERIMENTAL
Intervention: Dietary practices of adolescents (e.g., sugary snacks, breakfast consumption)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Dietary practices of females
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Dietary practices in rural areas
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Dietary practices in urban areas
Number of subjects: 1360
Study: 33526030

Group type: EXPERIMENTAL
Intervention: CARD™ intervention (C-Comfort, A-Ask, R-Relax, D-Distract)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 219
Study: 33285419

Group type: EXPERIMENTAL
Intervention: Expanded PrEP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV testing alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV testing alongside ART + PrEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expanded ART alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaling up PrEP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV testing (alone or with ART + PrEP)
Number of subjects: 0
Study: 36261400

Group type: EXPERIMENTAL
Intervention: O-R toothbrush (Oral-B iO with Radiant White brush head)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B Indicator)
Number of subjects: 100
Study: 34254372

Group type: EXPERIMENTAL
Intervention: Cornus mas L. fruit extract (CMFE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35006328

Group type: EXPERIMENTAL
Intervention: Carbohydrate therapy (CHO) group received a 400‐mL carbohydrate drink 2‐3 hours before anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group underwent overnight fasting from midnight, one night before surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carbohydrate therapy (CHO) group
Number of subjects: 50
Study: 33235033

Group type: EXPERIMENTAL
Intervention: Intervention group (n=142)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (n=138)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Medium levels of PA
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: High levels of PA
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Moderate intensity PA
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Vigorous intensity PA
Number of subjects: 280
Study: 34112291

Group type: EXPERIMENTAL
Intervention: Intermittent oro-esophageal tube feeding (IOE) combined with Xuanqiaoliyan decoction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine swallowing function training (control group)
Number of subjects: 100
Study: 35543940

Group type: EXPERIMENTAL
Intervention: Warming acupuncture combined with 'three steps and seven methods' of tuina
Number of subjects: 138

Group type: COMPARATOR
Intervention: Simple 'three steps and seven methods' of tuina
Number of subjects: 138
Study: 33210831

Group type: EXPERIMENTAL
Intervention: TALK SWI
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: TALK SWI plus Living Donor Financial Assistance
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 300
Study: 35689033

Group type: EXPERIMENTAL
Intervention: Early mobilization (wrist motion exercise immediately after surgery)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Delayed mobilization (wrist motion exercise after 2 weeks of external immobilization)
Number of subjects: 48
Study: 34760020

Group type: EXPERIMENTAL
Intervention: Garlic supplementation (one tablet daily for three consecutive cycles)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (one tablet daily for three consecutive cycles)
Number of subjects: 129
Study: 36184780

Group type: EXPERIMENTAL
Intervention: tirzepatide 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: tirzepatide 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: tirzepatide 15 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: dulaglutide 0.75 mg
Number of subjects: 48
Study: 33685969

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 82
Study: 32698790

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab and atezolizumab
Number of subjects: 201

Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 201
Study: 35998958

Group type: EXPERIMENTAL
Intervention: Perioperative support programme consisting of four face-to-face intervention sessions during the hospital stay and two weekly telephone follow-up sessions after discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 34096755

Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted psychotherapy (PAP) using compounds such as MDMA, psilocybin, and LSD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32017253

Group type: EXPERIMENTAL
Intervention: Curcumin 1,000 mg/day for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 70
Study: 36224529

Group type: EXPERIMENTAL
Intervention: Simulation-based holistic health-care education (3.5 hours)
Number of subjects: 30
Study: 32617578

Group type: EXPERIMENTAL
Intervention: Aliskiren added to an angiotensin II receptor blocker (ARB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (ARB alone)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 32671537

Group type: EXPERIMENTAL
Intervention: Test 1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test 3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test 4
Number of subjects: 120
Study: 34898303

Group type: EXPERIMENTAL
Intervention: Endothelin-1 levels on day-5
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Receiver Operating Curve analysis for day-5 Endothelin-1
Number of subjects: 96
Study: 36974773

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 8537

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 8537

Group type: EXPERIMENTAL
Intervention: Less fit status
Number of subjects: 8537

Group type: EXPERIMENTAL
Intervention: Frail status
Number of subjects: 8537
Study: 32767696

Group type: COMPARATOR
Intervention: Control group of a randomized controlled trial testing a care transitions intervention
Number of subjects: 699
Study: 32936595

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary behavior (SB)
Number of subjects: 30
Study: 36256673

Group type: EXPERIMENTAL
Intervention: Specific cough technique (SCT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Forced expiration technique (FET)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Saline inhalation with SCT
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline inhalation with FET
Number of subjects: 6
Study: 33827349

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling Exercise on Land (HIIE-L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling Exercise in Water (HIIE-A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Condition (CONT)
Number of subjects: 10
Study: 34101918

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sublingual dexmedetomidine
Number of subjects: 42
Study: 33479044

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Behavioural physical activity interventions
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity experience
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: COPD exacerbations
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: D-PPAC and C-PPAC instruments
Number of subjects: 1324
Study: 33109218

Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lucerastat 4000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lucerastat (up to 4000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study: 35928975

Group type: EXPERIMENTAL
Intervention: Modified Lamaze breathing
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 85
Study: 34225174

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Nocturnal Supplemental Oxygen (NSO)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Healthy Lifestyle and Sleep Hygiene Education (HLSE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: SQI (Sleep Quality Index) improvement
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: SAI (Sleep Apnea Indicator) increase
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: CPC-sleep fragmentation (eLFCBB) increase
Number of subjects: 241
Study: 35978342

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide for 12 weeks after culture conversion.
Number of subjects: 926

Group type: COMPARATOR
Intervention: Control group treated with isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide for 6 months.
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin regimen.
Number of subjects: 926